No significant differences in the postmortem interval in Myanmar and Japanese using vitreous potassium levels

Myo-Thaik-Oo(University of Tsukuba), Shogo Misawa(University of Tsukuba), Kumi Aita(University of Tsukuba), Kozo Tanno(Iwate Medical University), Einosuke Tanaka(University of Tsukuba), Haruna Oikawa(University of Tsukuba), Kentaro Yamazaki(Shizuoka Cancer Center)

Journal of Clinical Forensic Medicine

June 1, 2002

10.1054/jcfm.2002.0552

Cited by 11

Related Papers

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

|International Journal of Clinical Oncology|2017|2.5k

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer

|International Journal of Clinical Oncology|2019|2k

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

|The Lancet Oncology|2015|954

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

|Annals of Oncology|2017|591

Genome-wide association study identifies 112 new loci for body mass index in the Japanese population

|Nature Genetics|2017|510